Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects - Kosloski, Matthew P.; Zhao, Weihan; Marbury, Thomas C.; Preston, Richard A.; Collins, Michael G.; Pugatch, David; Mensa, Federico; Kort, Jens; Liu, Wei (Antimicrobial agents and chemotherapy, 2018)
Keywords: Adult; Aged; Antiviral Agents; Antiviral Agents - blood; Antiviral Agents - pharmacokinetics; Area Under Curve; Benzimidazoles; Benzimidazoles - blood; Benzimidazoles - pharmacokinetics; Drug Administration Schedule; Drug Therapy, Combination - methods; Female; Glomerular Filtration Rate - physiology; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - physiopathology; Male; Middle Aged; Quinoxalines; Quinoxalines - blood; Quinoxalines - pharmacokinetics; Renal Dialysis; Renal Insufficiency, Chronic; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - physiopathology; Sulfonamides; Sulfonamides - blood; Sulfonamides - pharmacokinetics; chronic kidney disease; pibrentasvir; hemodialysis; hepatitis C virus; pharmacokinetics; glecaprevir; renal impairment